Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.
vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling molecule involved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 11, 2019 | Private Equity(PE) | €9.50M | 3 | EF Investments | — | Detail |
Jan 21, 2016 | Series G | €20M | 1 | — | — | Detail |
Jun 24, 2013 | Series F | $6.50M | 1 | — | — | Detail |
Jan 30, 2006 | Series B | $11.80M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
EF Investments | Yes | Private Equity(PE) |
Future Capital Development Fund | — | Private Equity(PE) |
Bayern Kapital | — | Private Equity(PE) |